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List of abbreviations: 
ABP - arterial blood pressure 
AT1A - angiotensin II receptor type 1a 
AT1B - angiotensin II receptor type 1b  
AT2 - angiotensin II receptor type 2  
ATG – angiotensinogen 
DBP, SBP - Diastolic and systolic arterial blood pressure 
FCS - fluorescence correlation spectroscopy 
HF - heart failure 
HR - heart rate 
HPS – hydrostatic pressure stress 
ISO – isoprenaline 
LDH - lactate dehydrogenase 
LVP - left ventricle pressure 
PBS - phosphate buffer saline 
SD - Sprague-Dawley 
SHHF - Spontaneously-Hypertensive-Heart-Failure 
TGF-b - transforming growth factor-beta  
TIMP2 - metalloproteinase inhibitor 2  
TMA - trimethylamine 
TMAO – trimethylamine N-oxide 
UNa, UK - Urine sodium and potassium concentration 
UosmV, UNaV, UKV - the excretion of total solutes, sodium and potassium 
V - Urine flow  
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ABSTRACT 
Trimethylamine-oxide (TMAO) is present in seafood which is considered to be beneficial for 
health. Deep-water animals accumulate TMAO to protect proteins, such as lactate 
dehydrogenase (LDH), against hydrostatic pressure stress (HPS). We hypothesized that 
TMAO exerts beneficial effects on the circulatory system and protects cardiac LDH exposed 
to HPS produced by the contracting heart. Male, Sprague-Dawley and Spontaneously-
Hypertensive-Heart-Failure (SHHF) rats were treated orally with either water (control) or 
TMAO. In vitro, LDH with or without TMAO was exposed to HPS and was evaluated using 
fluorescence correlation spectroscopy. TMAO-treated rats showed higher diuresis and 
natriuresis, lower arterial pressure and plasma NT-proBNP. Survival in SHHF-control was 
66% vs 100% in SHHF-TMAO. In vitro, exposure of LDH to HPS with or without TMAO 
did not affect protein structure. In conclusion, TMAO reduced mortality in SHHF, which was 
associated with diuretic, natriuretic and hypotensive effects. HPS and TMAO did not affect 
LDH protein structure. 
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IMPACT STATEMENT 
Trimethylamine-oxide (TMAO), a molecule present in seafood, reduces mortality and exerts 
beneficial effects on the circulatory system in heart failure rats. 
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INTRODUCTION 4 
Some clinical studies have shown that increased levels of TMAO in the plasma are associated 5 
with an increased risk of adverse cardiovascular events (1-3). However, other studies have not 6 
confirmed this relationship (4-6). Furthermore, basic research data regarding the effect of 7 
TMAO on the circulatory system are contradictory (7-11).  8 
In the plasma, TMAO originates from the liver oxidation of trimethylamine (TMA), a product 9 
of gut bacteria metabolism of l-carnitine and choline (12, 13). However, another direct source 10 
of TMAO in humans is TMAO-rich seafood (14, 15). Therefore, populations whose diet are 11 
rich in seafood, such as the Japanese, have higher urine TMAO concentrations than those that 12 
do not, for example, Americans (16, 17). Interestingly, prevalence and mortality rates of heart 13 
failure (HF) are lower in Japan compared to the US or Europe, despite the fact that Japan has 14 
the highest proportion of elderly people in the world (18-19). 15 
Marine animals living in deep water, and thus exposed to hydrostatic pressure stress (HPS), 16 
accumulate TMAO (15, 20-23). Data from biophysical experiments suggest a protective effect 17 
of TMAO on cell proteins exposed to HPS. For example, TMAO has been found to stabilize 18 
teleost and mammalian lactate dehydrogenase (LDH), a complex tetramer protein that plays 19 
an essential role in cellular metabolism (21). 20 
Notably, in a heart exposed to catecholamine-induced stress or in a hypertensive heart, 21 
diastolic-systolic changes in pressure may exceed 220 mmHg. These fluctuations in pressure 22 
can happen in humans up to 200 times per minute. These numbers are even higher in small 23 
animals. These events may produce an environment in which the hydrostatic pressure changes 24 
approximately 100 000 times in 24 hours. However, the effect of HPS produced by the 25 
contracting heart on cardiac proteins is obscure. 26 
Recently, we hypothesized that TMAO may benefit the circulatory system by protecting 27 
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cardiac LDH exposed to HPS produced by diastole-systole-driven changes in the hydrostatic 28 
pressure of the contracting heart (24).  Here, we investigated whether a continuous, 12-29 
months-long oral administration of TMAO in healthy Sprague-Dawley rats (SD), in SD 30 
exposed to catecholamine stress, and in animal model of heart failure (HF) with reduced 31 
ejection fraction (SHHF) exerts beneficial effects on the circulatory system. Furthermore, we 32 
evaluated whether TMAO protects the protein structure of cardiac LDH exposed to HPS. To 33 
examine the effects of HPS in the context that mimics the environment produced by the 34 
contracting heart, we developed a novel experimental system using microfluidics chambers 35 
with piezoelectric valves and pressure controllers. 36 
 37 
RESULTS 38 
Spontaneously Hypertensive Heart Failure (SHHF) and age-matched Sprague-Dawley (SD) 39 
rats were randomly assigned to either the control group (rats drinking tap water) or the TMAO 40 
group (rats drinking TMAO solution in tap water). At the age of 56 weeks, the ISO-control 41 
and ISO-TMAO series were given isoprenaline at a dose of 100 mg/kg b.w. to produce 42 
catecholamine stress. The experimental protocol is depicted in Figure 1. 43 
 44 
SD rats 45 
In general SD rats showed no pathological findings (Table 1, Figure 6, 7, and supplement 46 
Figure 7-figure supplement 1). 47 
SD rats: Control vs TMAO treatment 48 
Survival and water-electrolyte balance 49 
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There was no significant difference between the SD-control and SD-TMAO rats in survival 50 
rate (100% in both groups), body mass and food intake. The SD-TMAO rats showed 5-times 51 
higher plasma TMAO levels than the SD-control group. The SD-TMAO group showed a 52 
significantly higher 24hr urine output and sodium urine excretion. There was no significant 53 
difference between the SD-TMAO and SD-control group in plasma Ang II and aldosterone 54 
level. However, the SD-TMAO rats showed higher vasopressin concentration (Table 1). 55 
Circulatory parameters  56 
There was no significant difference between the SD-control and SD-TMAO group in 57 
hemodynamic parameters measured directly and with echocardiography, however, the SD-58 
TMAO rats showed higher SV and HR (Table 1). 59 
Histopathology  60 
There were no pathological changes in the heart, lungs and kidneys in either the SD-control or 61 
SD-TMAO group (Figure 7 and Figure 7-figure supplement 1).  62 
Gene expression 63 
The SD-TMAO rats showed significantly lower expression of AT1 receptors (AT1R) in the 64 
heart. In the kidneys, SD-TMAO rats showed significantly higher expression of renin but 65 
lower expression of AT2 receptors (AT2R) and a trend towards a lower expression of AT1R 66 
(Figure 8, 9). 67 
 68 
SHHF rats 69 
In general, the SHHF animals showed characteristics of hypertrophic cardiomyopathy with 70 
compromised systolic function including substantially increased heart mass and plasma NT-71 
proBNP, decreased stroke volume and ejection fraction as well as lung edema (Table 2, 72 
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Figure 6). Histological evaluation of the heart revealed dilated cardiomyopathy i.e. a moderate 73 
increase in the diameter of cardiomyocytes, enlargement of the nucleus and a reduction of 74 
cytoplasmic acidity (Figure 10). In the lungs, a passive hyperemia with thickening of the 75 
interalveolar septa, a weak focal parenchymal edema and a moderate stromal connective 76 
tissue hyperplasia were present. There were no significant pathological changes in the kidneys 77 
(Figure 10). 78 
SHHF rats: Control vs TMAO treatment 79 
Survival and water-electrolyte balance 80 
All SHHF-TMAO rats (n=9) survived from the beginning of the experiment till the age of 58-81 
weeks, i.e. the time of anesthesia before echocardiography. In contrast, three out of nine 82 
animals (33%) in the SHHF-control group died. Specifically, two rats were euthanized due to 83 
hemiparalysis (ischemic stroke) and dyspnea (post-mortem lung edema), and one died 84 
spontaneously (post-mortem lung edema), at the age of 52, 56 and 57-weeks, respectively. 85 
The log-rank test showed a trend (p=0.0651) towards higher survival in the SHHF-TMAO 86 
than in SHHF-control group (Figure 11). One SHHF-TMAO animal died during anesthesia 87 
before echocardiographic examination. The following numbers in each group were included 88 
for further analysis: SHHF-TMAO (n=8) and SHHF-control (n=6).   89 
There was no significant difference between the groups in food intake. The SHHF-TMAO 90 
animals showed 3-4-fold higher plasma TMAO level than the SHHF-control rats. The SHHF-91 
TMAO rats had a significantly higher 24hr urine output and sodium excretion than the SHHF-92 
control rats. The SHHF-TMAO group showed significantly lower plasma sodium and Ang II 93 
levels, but there were no differences in aldosterone and vasopressin plasma levels (Table 2). 94 
Circulatory parameters 95 
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The SHHF-control and SHHF-TMAO group showed hypertrophic cardiomyopathy with 96 
compromised systolic functions and increased plasma NT-proBNP (Figure 6 and 10, Table 2). 97 
The SHHF-TMAO rats had a significantly lower diastolic blood pressure and a trend towards 98 
lower plasma NT-proBNP (p=0.09), higher stroke volume (p=0.053) and higher ejection 99 
fraction (p=0.06), (Table 2). 100 
Histopathology 101 
The general histological picture of myocardium and cardiomyocyte morphology did not differ 102 
significantly between the groups. Morphometric analysis did not show significant differences 103 
in the degree of myocardial fibrosis between the groups. However, in the TMAO group there 104 
was a trend towards less myocardial fibrosis (p=0.07), cardiomyocyte bands were more 105 
visible, and smaller inflammatory infiltration was found. The histological picture of the lungs 106 
and kidneys did not differ significantly between SHHF-control and SHHF-TMAO groups 107 
(Figure 10). 108 
Gene expression 109 
The SHHF-TMAO rats had a significantly lower expression of AT1R and a significantly 110 
higher expression of AT2R in the heart. In the kidneys, the SHHF-TMAO rats showed a 111 
significantly higher expression of renin and lower expression of AT1AR (Figure 8 and 9).  112 
 113 
SD-ISO rats 114 
In general, the SD animals subjected to catecholamine stress (isoprenaline) showed some 115 
characteristics of Takotsubo-like cardiomyopathy, including a mild degree of apical 116 
akinesis/dyskinesis, edema of cardiomyocytes, increased NT-proBNP level and mild lung 117 
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edema (Figure 6 and 12, Table 3). Numerous, scattered foci of banded mononuclear cell 118 
infiltration were present in the myocardium. Severe hyperemia of myocardial capillaries and 119 
arterioles and small organized foci of myocardial extravasation were present. Nevertheless, 120 
the majority of the myocardium remained normal in structure. The lungs presented transudate 121 
in the alveoli. In the kidneys, there was a weak congestion in the medulla and renal bodies. A 122 
small number of tubules filled with an acidic substance was present. Stimulation of stromal 123 
fibrocytes without production of connective tissue fibers was observed (Figure 12). 124 
 125 
SD-ISO rats: Control vs TMAO treatment 126 
Survival and water-electrolyte balance 127 
There was no significant difference between ISO-control and ISO-TMAO groups in survival 128 
rate (9/10 vs 10/10, respectively). The ISO-TMAO rats showed 5 times higher TMAO plasma 129 
level than the ISO-control rats. There was no significant difference in food and water intake 130 
between the groups. There was also no significant difference between the groups in 24hr urine 131 
output, however, the ISO-TMAO rats tended to have higher natriuresis (Table 3).   132 
Circulatory parameters  133 
The ISO-TMAO rats showed significantly lower systolic and diastolic blood pressure, 134 
significantly lower plasma NT-proBNP and lower LV ESV and LVEDP (Table 3).   135 
Histopathology 136 
The histological picture of the heart, lungs and kidneys did not differ significantly between 137 
the groups (Figure 12).  138 
Gene expression 139 
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In the heart, the ISO-TMAO rats showed significantly lower expression of ATG, AT1R and 140 
AT2R. In the kidneys, the ISO-TMAO rats showed significantly lower expression of ATG 141 
and AT1R and significantly higher expression of renin (Figure 8 and 9).  142 
 143 
Effect of TMAO on renal excretion in SD rats - acute studies 144 
We evaluated changes in renal excretion induced by TMAO, urea and saline intravenous 145 
administration in acute experiments. Results are summarized in Figure 13. Only TMAO 146 
induced diuresis. The pattern of  diuresis and total solutes excretion induced by TMAO were 147 
similar. Increases of V and UosmV induced by TMAO were associated with transient 148 
decrease of Uosm, whereas UNaV and UKV were not affected. This indicates that TMAO did 149 
not affected the tubular transport of sodium and  potassium but induced osmotic diuresis. The 150 
bolus infusions of TMAO or saline produced a transient increase in ABP with no changes in 151 
HR, which was followed by a decrease in ABP below the baseline (by 6±3 mmHg). There 152 
was no significant correlation between changes in ABP and diuresis. 153 
 154 
Effect of TMAO on structure of LDH exposed to HPS and increased temperature 155 
Labeled LDH was stable in PBS solution, showing no tendency for spontaneous aggregation. 156 
The value of diffusion coefficients measured by FCS at 25°C was 49.2±3.3 μm2/s. This 157 
corresponds to a hydrodynamic radius of around 5.0 nm, which is in line with previously 158 
reported values (25).  159 
The tertiary and quaternary structures of LDH, with and without TMAO, were not influenced 160 
by a 24 hrs treatment with HPS (pressure oscillations mimicking those of a rat heart), (Figure 161 
14 A). Tests performed using a different pressure oscillation system, where pressures up to 162 
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1000 mmHg were applied, did not detect observable changes in the protein structure (see 163 
Figure 14-figure supplement 1). 164 
The incubation of LDH at atmospheric pressure and elevated temperatures (50 – 80°C) 165 
changed the diffusion coefficient of LDH, indicating the dissociation of LDH tetramers, as 166 
well as protein denaturation and aggregation. The addition of 1M TMAO produced a 167 
moderate stabilizing effect on LDH, shifting the threshold of observed protein morphology 168 
change towards higher temperatures (Figure 14 B). Specifically, it seems that the gradual 169 
dissociation of tetramers to monomers occurred above 55°C, which was followed by the 170 
denaturation of the tertiary protein structure at higher temperatures. At a concentration of 171 
LDH > 3nM, the aggregation of monomers prevailed. At a lower concentration, the 172 
aggregation progressed more slowly, if at all, while any aggregates that did form, were too 173 
sparse to influence the measurement results. Further work, including probing a broader matrix 174 
of LDH concentrations and temperatures, is needed to confirm these initial findings. 175 
Nevertheless, in all the experiments, presence of TMAO shifted the threshold of change in 176 
LDH morphology towards higher temperatures and diminished the magnitude of the change. 177 
This suggests a stabilizing effect of TMAO on the native structure of the protein. 178 
 179 
DISCUSSION 180 
Our study provides evidence that TMAO exerts a beneficial effect in heart failure rats. The 181 
beneficial effect of TMAO is associated with diuretic, natriuretic and hypotensive actions 182 
rather than a stabilizing effect on cardiac LDH. Specifically, we found that HPS at the 183 
magnitude substantially greater than that generated by a contracting heart did not affect 184 
cardiac LDH protein structure with or without TMAO. 185 
Plasma TMAO originates from trimethylamine (TMA), a product of gut bacteria, which is 186 
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oxidized by the liver to form TMAO. It can also be obtained from dietary TMAO-rich 187 
seafood (12, 13). Several years ago, Tang and collaborators showed that increased plasma 188 
TMAO is associated with an increased risk of major adverse cardiovascular events (3), which 189 
generated numerous clinical and experimental studies, suggesting negative effects of TMAO 190 
(for review, (12, 26)).  However, other clinical studies did not find an association between 191 
high plasma TMAO and increased cardiovascular risk (4-6).  192 
Our previous studies suggest that TMAO is only a surrogate marker and that the toxic 193 
cardiovascular effects are caused not by TMAO itself, but by a TMAO precursor, i.e. TMA 194 
(27-29). Notably, the latter is a well-established toxin (30). Since TMA is oxidized (likely, 195 
detoxified) by the liver to TMAO, the increased plasma TMAO is simply a proxy to the 196 
plasma levels of the toxic TMA. What is more, recent experimental studies provide evidence 197 
for a beneficial action of TMAO at low doses (7-9).  198 
Here, we investigated the effect of TMAO in (i) healthy SD rats, (ii) SHHF 199 
(SHHF/MccGmiCrl-Lepr
cp
/Crl) which showed characteristics of heart failure with 200 
compromised systolic function and (iii) SD subjected to catecholamine stress (isoprenaline).  201 
Our findings show that increased dietary TMAO, which elevates plasma TMAO level 3-5-202 
fold, increased diuresis and natriuresis in SD and SHHF rats. This is associated with reduced 203 
mortality and favorable hemodynamic and biochemical changes in HF rats. 204 
In this study, during a stress-free 52-week observation, the fatality rate of the SHHF animals 205 
treated with TMAO was 0% in comparison to 33% in the untreated group. This was 206 
associated with several beneficial hemodynamic and biochemical characteristics in the 207 
TMAO-treated SHHF rats, namely; a lower diastolic BP, higher diuresis and natriuresis, a 208 
lower expression of AT1R in the heart with concomitant increase in AT2R, and a trend 209 
towards lower cardiac fibrosis. Regarding the latter, the tissue angiotensin system contributes 210 
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significantly to remodeling of the heart, and its inhibition is critical in the treatment of heart 211 
failure (31).  212 
Some of the characteristic features of HF are inflammation and increased sympathetic 213 
activity. In this regard, the SHHF-TMAO group had a significantly increased plasma level of 214 
IL-10, an anti-inflammatory cytokine, and a trend towards lower plasma TNF-α, a pro-215 
inflammatory mediator. Significantly lower diastolic blood pressure together with mildly 216 
lower heart rate may also suggest lower sympathetic activity in the SHHF-TMAO group. 217 
However, to fully address this issue further studies evaluating concentration of 218 
catecholamines metabolites in urine are needed. It is worth stressing that due to the high 219 
mortality in the SHHF-control group, the final analysis of hemodynamic and biochemical 220 
parameters included only the survivors i.e., the healthiest rats. It is interesting to speculate, 221 
had all the SHHF-control rats survived to the experimental endpoints, whether the differences 222 
between the SHHF-TMAO and SHHF-control would have been even greater.  223 
Finally, a key characteristic of HF is fluid retention. We think that the beneficial effects of 224 
TMAO described above were secondary to the TMAO-produced increase in diuresis and 225 
natriuresis, which is a cornerstones of HF treatment. 226 
We assumed that the diuretic and natriuretic effects of TMAO resulted from osmotic diuresis. 227 
To evaluate the notion, we performed additional acute experiments in rats. We found that 228 
intravenous administration of TMAO, but not saline given at the same volume, significantly 229 
increased diuresis in anesthetized rats. Furthermore, in chronic studies, TMAO-treated rats 230 
showed increased expression of renin in the kidneys. This is a characteristic response to 231 
osmotic diuresis, associated with a decreased concentration of sodium in filtrate reaching 232 
distal convoluted tubule. Increased diuresis in TMAO-treated rats was present despite 233 
elevated plasma levels of vasopressin which allows the reabsorption of water from the filtrate 234 
in collecting ducts. The reabsorption is driven by the osmotic pressure gradient between the 235 
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filtrate and the kidney medulla. In TMAO-treated rats, the osmotic gradient was likely 236 
decreased due to the high osmotic activity of TMAO and high TMAO levels in the filtrate. 237 
This could decrease the reabsorption of water from the filtrate despite the vasopressin-induced 238 
increase in the permeability of collecting ducts to water. 239 
To evaluate diuretic effect of TMAO, we compared TMAO to urea, which was used as a 240 
diuretic treatment of advanced HF before being replaced by thiazide diuretics (32, 33). 241 
Notably, both molecules are nitrogenous compounds, have a similar molecular weight, and 242 
play the role of an osmolyte in animals (15). In our experiments, TMAO produced significant 243 
diuresis whereas urea did not. This was likely due the fact that we evaluated the same 244 
(equimolar) doses of urea and TMAO, whereas physiological concentrations of TMAO in the 245 
plasma is radically lower (micromoles/L) in comparison to urea (millimoles/L). Therefore, 246 
our findings suggest that TMAO exerts a significantly more potent diuretic effect than urea. 247 
A number of biological and biophysical studies indicate that TMAO is not only an osmolyte 248 
but also a piezolyte, i.e., stabilizes structural proteins and enzymes, such as LDH, in 249 
conditions of increased hydrostatic pressure (21-23). Therefore, the accumulation of TMAO 250 
in the bodies of deep-water animals may protect cell proteins from HPS (15, 21). 251 
The effect of HPS produced by the contracting heart on cardiac proteins is unclear. Based on 252 
studies showing that TMAO stabilizes teleost and mammalian lactate dehydrogenases against 253 
inactivation by hydrostatic pressure (21, 34, 35), we hypothesized that TMAO may exert a 254 
protective effect on the circulatory system by stabilizing the protein structure of cardiac LDH, 255 
a complex enzyme that plays essential role in cardiac metabolism (24). 256 
To evaluate this hypothesis, we built a unique experimental setup to mimic the changes in 257 
hydrostatic pressure that occur in the heart under conditions of catecholamine stress. These in 258 
vitro experiments showed that changes in hydrostatic pressure generated by the contracting 259 
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heart, and even much higher pressures, do not disturb the protein structure of cardiac LDH. 260 
Finally, the addition of TMAO did not produce any effect, suggesting neither positive nor 261 
negative effect of TMAO on LDH exposed to HPS. Nevertheless, we showed that TMAO 262 
stabilized LDH exposed to other denaturant, i.e. high temperature, which is in line with other 263 
studies (36). In general, changes in protein structure lead to perturbed (or even the loss of) 264 
activity of proteins. However, further studies are needed to evaluate if LDH activity would be 265 
affected by HPS, TMAO and temperature in a similar manner as LDH protein structure. 266 
Altogether, our study shows that TMAO exerts beneficial effects in cardiovascular 267 
pathologies associated with fluid retention such as HF. The beneficial effects of TMAO 268 
appear to stem from its diuretic action rather than from the protein-stabilizing effect of 269 
TMAO on LDH, which was described for deep-sea animals, but was found not be involved 270 
here. It may be that the hydrostatic pressure generated by a contracting heart is far lower than 271 
the deep‐sea pressures and is kinetic (pulsing and moving) rather than static. In this regard, 272 
there is evidence that static pressure may have very different effects on cells and proteins than 273 
kinetic pressure (37). Nevertheless, the stabilizing effect of TMAO on other, less stable, 274 
cardiac proteins exposed to HPS cannot be excluded.  275 
Limitations 276 
A limitation of our study is that biochemical and hemodynamic measurements were 277 
performed only at the end of the treatment. This is because we aimed to avoid stress-related 278 
circulatory complications in SHHF rats, which are very prone to lethal cardiovascular events. 279 
Conclusions 280 
TMAO, a molecule present in seafood and a derivate of gut bacteria metabolism, exerts 281 
beneficial effects in HF rats. These benefits might be derived from the diuretic, natriuretic and 282 
hypotensive properties of TMAO. The hydrostatic pressure stress generated by the contracting 283 
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heart does not affect LDH protein structure. Further studies designed to evaluate TMAO-284 
dependent diuretic and natriuretic effects are needed, as TMAO may serve as a naturally 285 
occurring diuretic agent in diseases associated with fluid retention e.g. heart failure. 286 
 287 
MATERIALS AND METHODS 288 
Key Resources Table 
Reagent 
type 
(species) 
or 
resource 
Designation 
Source or 
reference 
Identifiers 
Additional 
informatio
n 
strain, 
strain 
background 
(Rattus 
norvegicus, 
male) 
SHHF/MccGmi
Crl-Leprcp/Crl 
Charles 
River 
Laboratories 
(USA) 
 RRID:RGD_231322
1 
  
commercial 
assay or kit 
 NT-proBNP  FineTest  cat. no. ER0309   
commercial 
assay or kit 
aldosterone 
Cayman 
Chemicals 
cat. no. 501090  
commercial 
assay or kit 
vasopressin Biorbyt cat. no. orb410987  
commercial 
assay or kit 
angiotensin II FineTest cat. no. ER1637  
commercial 
assay or kit 
TNFα R&D System cat. no. RTA00  
commercial 
assay or kit 
IL-10 R&D System cat. no. R1000  
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commercial 
assay or kit 
angiotensinoge
n 
Bio-Rad 
Unique Assay ID: 
qRnoCED0051666 
 
commercial 
assay or kit 
angiotensin II 
receptor type 
1a 
Bio-Rad 
Unique Assay ID: 
qRnoCID0052626 
 
commercial 
assay or kit 
angiotensin II 
receptor type 
1b 
Bio-Rad 
Unique Assay ID: 
qRnoCED0005729 
 
commercial 
assay or kit 
angiotensin II 
receptor type 2 
Bio-Rad 
Unique Assay ID: 
qRnoCED0007551 
 
commercial 
assay or kit 
transforming 
growth factor-
beta 
Bio-Rad 
Unique Assay ID: 
qRnoCED0007638 
 
commercial 
assay or kit 
renin Bio-Rad 
Unique Assay ID: 
qRnoCID0008721 
 
commercial 
assay or kit 
metalloproteina
se inhibitor 2 
Bio-Rad 
Unique Assay ID: 
qRnoCID0001559 
 
commercial 
assay or kit 
Beta-actin Bio-Rad 
Unique Assay ID: 
qRnoCED0018219 
 
chemical 
compound, 
drug 
TMAO  abcr GmbH cat. no. AB 109058 
 
chemical 
compound, 
drug 
isoprenaline 
hydrochloride 
Sigma-
Aldrich 
cat. no. I5627  
software, 
algorithm 
CFX Manager Bio-Rad RRID:SCR_017251 
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software, 
algorithm 
SymPhoTime 
64 
PicoQuant RRID:SCR_016263  
software, 
algorithm 
AcqKnowledge 
Software 
Biopac 
Systems, Inc. 
RRID:SCR_014279  
 289 
All source data are available as supplementary material. 290 
Animals 291 
The study was performed according to Directive 2010/63 EU on the protection of animals 292 
used for scientific purposes and approved by the Local Bioethical Committee in Warsaw 293 
(permission:100/2016 and 098/2019). 4-5-week-old, male, lean Spontaneously Hypertensive 294 
Heart Failure (SHHF/MccGmiCrl-Lepr
cp
/Crl) rats were purchased from Charles River 295 
Laboratories (USA). Age-matched Sprague-Dawley (SD) rats were obtained from the Central 296 
Laboratory for Experimental Animals, Medical University of Warsaw, Poland. 297 
Study protocol 298 
Six-week-old SHHF (n=18) and SD (n=40) were randomly assigned to either control groups 299 
(rats drinking tap water) or the TMAO groups (rats drinking TMAO solution in tap water, 300 
TMAO - abcr GmbH - Karlsruhe, Germany, 333 mg/l). While no specific randomization 301 
method was used, rats from one cage were assigned to different groups. The dose of TMAO 302 
was selected in order to increase the plasma TMAO concentration by 3-5 times (to mimic 303 
possible physiological concentrations) and to avoid suprapharmacological effects of TMAO, 304 
based on our previous study (7). 305 
Rats were housed in groups of 2-3 animals, in polypropylene cages with environmental 306 
enrichment, 12 hrs light / 12 hrs dark cycle, temperature 22-23 oC, humidity 45-55 %, fed 307 
standard laboratory diet (0.19 % Na, Labofeed B standard, Kcynia, Poland) and water ad 308 
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libitum. 309 
SHHF-TMAO (n=9), SHFF-control (n=9), SD-TMAO (n=10), SD-control (n=10) were not 310 
subjected to any interventions except standard animal care until the age of 58 weeks. At the 311 
age of 56 weeks the ISO-control (n=10) and ISO-TMAO (n=10) series were given (s.c.) 312 
isoprenaline at a dose of 100 mg/kg b.w. (isoprenaline hydrochloride, Sigma-Aldrich, Saint 313 
Louis, MO, USA) to produce catecholamine stress as previously described (38). The 314 
experimental protocol is depicted in Figure 1. 315 
Experimental protocol in SD and SHHF 316 
58-week-old rats were maintained in metabolic cages for 2 days to evaluate the 24hr water 317 
and food balance and to collect urine for analysis. The next day, the rats underwent an 318 
echocardiogram using a Samsung HM70: an ultrasound system equipped with a linear probe 319 
5-13. MHz. After the echo examination the rats were anaesthetized with urethane (1.5 g/kg 320 
b.w. i.p., Sigma-Aldrich) and the left femoral artery was cannulated with a polyurethane 321 
catheter for arterial blood pressure (ABP) recordings. The recordings were started 40 min 322 
after the induction of anesthesia and 15 min after inserting the arterial catheter. After 10 min 323 
of ABP recordings, a Millar Mikro-Tip SPR-320 (2F) pressure catheter was inserted via the 324 
right common carotid artery and simultaneous left ventricle pressure (LVP) and ABP 325 
recordings were performed. The catheter was connected to a Millar Transducer PCU-2000 326 
Dual Channel Pressure Control Unit (Millar, USA) and Biopac MP 150 (Biopac Systems, 327 
USA). After hemodynamic recordings, blood from the right ventricle of the heart was taken 328 
and rats were euthanized by decapitation. The heart, the lungs and the kidneys were harvested 329 
for histological and molecular analysis. 330 
Experimental protocol in SD-ISO 331 
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56-week-old rats were housed in metabolic cages for 2 days to evaluate the 24hr water and 332 
food balance and to collect urine for analysis. Echocardiography was performed as described 333 
above. The next day, rats were given isoprenaline (100 mg/kg, s.c.). 24hrs after the 334 
administration of ISO, the echocardiogram  was repeated. Eight days after the ISO-treatment, 335 
the 24hr food and water intake was evaluated and an echocardiogram was performed. 336 
Afterwards, the rats were anaesthetized with urethane (1.5 g/kg b.w. i.p., Sigma-Aldrich, 337 
Poland) and the hemodynamic measurements were taken, including ABP and LVP recordings 338 
as described above for SHHF and SD rats. 339 
TMAO and general biochemistry evaluation  340 
Plasma and urine concentrations of TMAO were measured using Waters Acquity Ultra 341 
Performance Liquid Chromatograph coupled with a Waters TQ-S triple-quadrupole mass 342 
spectrometer. The mass spectrometer was operated in the multiple-reaction monitoring 343 
(MRM) - positive electrospray ionization (ESI) mode, as previously described (39). 344 
Serum and urine sodium, potassium, creatinine and urea were analyzed using a Cobas 6000 345 
analyzer (Roche Diagnostics, Indianapolis, USA). 346 
ELISA test 347 
The following ELISA kits were used for the evaluation: NT-proBNP (FineTest, cat. no. 348 
ER0309), aldosterone (Cayman Chemicals, cat. no. 501090), vasopressin (Biorbyt, cat. no. 349 
orb410987), angiotensin II (FineTest, cat. no. ER1637), TNFα and IL-10 (cat. no. RTA00 and 350 
R1000, respectively, R&D System). All procedures were carried out according to the standard 351 
protocol supplied with the ELISA Kit. The absorbance intensity was measured at 450 nm with 352 
a Multiskan Microplate Reader (Thermo Fisher Scientific). All experiments were performed 353 
in duplicate (technical replicates). 354 
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Histopathological evaluation 355 
Tissues sections were fixed in 10% buffered formalin, dehydrated using graded ethanol and 356 
xylene baths and embedded in paraffin wax. Sections of 3–4 μm were stained with 357 
haematoxylin and eosin (HE) and van Gieson stain (for connective tissue fibers). General 358 
histopathological examination was evaluated at a magnification of 10x, 40x and 100x 359 
(objective lens) and 10x (eyepiece) and photographic documentation was taken. 360 
Morphometric measurements were performed at magnification of 40x (objective lens). 361 
Molecular Biological Procedures  362 
Heart and kidney samples were collected from rats under urethane anesthesia and frozen at -363 
80°C. Next, the samples were homogenized on BeadBug™ microtube homogenizer 364 
(Benchmark Scientific, Inc.). Total RNA was isolated from the samples according to the TRI 365 
Reagent® protocol. cDNA was transcribed from RNA samples according to the iScript™ 366 
Reverse Transcription Supermix #1708841 protocol (Bio-Rad). The qPCR mixes were 367 
prepared according to the Bio-Rad SsoAdvanced™ Universal SYBR® Green Supermix 368 
protocol #1725271. Amplifications were performed on a Bio-Rad CFX Connect Real-Time 369 
System under standardized conditions using commercial assays. Data were analyzed using 370 
CFX Manager 3.0 software. The genes investigated in this study were: angiotensinogen (Atg, 371 
qRnoCED0051666), angiotensin II receptor type 1a (At1a, qRnoCID0052626), angiotensin II 372 
receptor type 1b (At1b, qRnoCED0005729), angiotensin II receptor type 2 (At2, 373 
qRnoCED0007551), transforming growth factor-beta (Tgf-b, qRnoCED0007638), renin (Rn, 374 
qRnoCID0008721), metalloproteinase inhibitor 2 (Timp2, qRnoCID0001559). Beta-actin was 375 
used as housekeeping gene (Actbl2, qRnoCED0018219). 376 
The effect of TMAO on diuresis, acute experiments 377 
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Surgical preparations 378 
Male SD rats were anaesthetized with urethane 1.5 g/kg b.w. i.p., which provided stable 379 
anesthesia for at least 4 hours. The jugular vein was cannulated for fluid infusions, and the 380 
carotid artery for ABP measurement with the Biopac MP 150 (Biopac Systems, USA). The 381 
bladder was exposed with an abdominal incision and was cannulated for timed urine 382 
collection. After the surgery, 20-30 min was allowed for stabilization. During this time, 0.9% 383 
saline was infused intravenously at a rate of 5 ml/kg/h. After completion of all experiments, 384 
the rats were euthanized by decapitation and both kidneys were excised and weighed. 385 
Experimental procedures and measurements 386 
At the end of the stabilization period, three or four 10-min urine collections were taken to 387 
determine baseline water, sodium and total solute excretion rates in each experimental group. 388 
After stabilization of urine flow, TMAO (n=8) was infused first as a priming dose of 2.8 389 
mmol/kg b.w. in 5 mL / kg b.w. of 0.9% saline / 5 min, followed by an infusion delivering 2.8 390 
mmol/kg b.w. of TMAO in 5 mL/kg b.w of saline / 60 min. At the start of the priming 391 
injection, five 10-min urine collections were taken during the infusion of TMAO. This basic 392 
protocol was applied in the two following protocols where TMAO was replaced by its solvent 393 
(0.9% NaCl) or saline solution of urea (2.8 mmol/kg). 394 
(i) Effect of drug solvent infusion (n=5). These experiments served as a control for the 395 
equivalent volume administration of fluid bolus. 396 
(ii) Effect of hypertonic fluid infusion of urea (n=6). These experiments served as a 397 
control for equivalent volume administration of equivalent hypertonic fluid. The urea solution 398 
was equimolar with the solution of TMAO. 399 
Analytical procedures and calculations 400 
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Urine volume was determined gravimetrically. Urinary osmolality (Uosm) was measured with 401 
the cryoscopic Osmomat 030 osmometer (Gonotec, Berlin, Germany). Urine sodium (UNa) 402 
and potassium (UK) concentration were measured by a flame photometer (BWB-XP, BWB 403 
Technologies Ltd, Newbury, UK). Urine flow (V), the excretion of total solutes (UosmV), 404 
sodium (UNaV) and potassium (UKV) were calculated using the standard formulas and 405 
standardized to g kidney weight (UXV/g KW). All measurements were performed in 406 
duplicates (technical replicates). 407 
Oscillatory-pressure controller and fluorescence correlation spectroscopy 408 
We evaluated the effect of TMAO on bovine, cardiac LDH (Merck, Poland) exposed to 409 
pressure oscillations and increased temperature. The pressure oscillations were generated in a 410 
custom-built system.  In order to mimic the conditions in the heart the pressure changed from 411 
0 to 180–250 mmHg (or to higher values) at oscillation rate of 280 min-1. In general, the 412 
setup consisted of two main parts: i) a custom-built oscillatory pressure controller with 413 
solenoid micro valves to control the inner pressure and “pulse” frequency and ii) a sample 414 
chamber (Figure 2). We designed and constructed 3 different samples chambers (Figure 3, 4 415 
and 5), which permitted the samples to be exposed to pressure oscillations in different ways. 416 
 417 
Oscillatory pressure controller 418 
The custom-built oscillatory-pressure controller consisted of two pressure sources with 419 
constant but different air pressures (p1 and p2, respectively). Each pressure source was 420 
connected through a plunger-type solenoid microvalve (V165, Sirai, Italy) to the inlet/outlet 421 
of the sample chamber via Teflon tubes (ID/OD=0.8/1.6 mm, Bola, Germany) as shown in 422 
Figure 2. The two microvalves were controlled by a multiplexer switch module (National 423 
Instruments, USA) interfaced via custom-made LabView software which is freely available 424 
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from the Github repository (40). Due to their electro-magneto-mechanical construction the 425 
microvalves had some response time: the delay between application of the current and 426 
opening of the valve was 24 ms, and the delay between stopping the current and shutting the 427 
valve was 8 ms (41). The time shifts were taken into consideration when calculating the 428 
required oscillatory pressure. 429 
Operation protocol: The two valves were initially closed and the pressure inside the sample 430 
chamber was equal to the atmospheric pressure. Upon initiating the oscillatory system, the 431 
first valve opened for 50 ms. As the first valve closed, the second valve opened for 50 ms 432 
followed by a 50 ms pause when both valves were closed. With the response times included, 433 
one full cycle took 214 ms, generating an oscillation of ~280/minute between pressure p1 and 434 
p2, mimicking the heartbeat of a rat. This pressure-oscillatory system was used in each 435 
relevant experiment with the only difference being the pressure applied: p1 and p2. 436 
Microfluidic heart chip 437 
In the first set of experiments a microfluidic device was constructed in polydimethylsiloxane 438 
(PMDS; Sylgard 184, Dow Corning, USA) in three steps; first, the channels and sample 439 
chamber (in the shape of a heart) were micro-milled in a polycarbonate plate (PC; Macrolon, 440 
Germay) using a CNC milling machine (MSG4025, Ergwind, Poland); second, we poured 441 
PDMS onto the PC chip, polymerized the PDMS at 75°C for 2 hours, activated the surface 442 
using a Laboratory Corona Treater (BD 20AC, Electro-Technic Products, USA) and silanized 443 
in the vapours of tridecafluoro-1,1,2,2-tetrahydrooctyl-1-trichlorosilane (United Chemical 444 
Technologies, USA) for 60 min under vacuum (10mbar); third, this negative mold was used 445 
to produce the final PDMS chip. Inlet and outlet holes were punched using a small diameter 446 
(ID=0.8mm) biopsy puncher prior to bonding the PDMS chip  to 1mm-thick glass slides using 447 
oxygen plasma for 45s. 448 
Operation parameters. The inlets were connected to the heart-shaped sample chamber (height 449 
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of 300 µm and total volume of ~220µL) via microchannels from two sides (Figure 3a). On 450 
one side, the microchannel ended in a single inlet through which the sample liquid was 451 
injected. Once the chamber was completely filled, the inlet was sealed air-tight. On the other 452 
side of the chamber, the microchannel branched into two channels, ending in 1-1 inlets. The 453 
two ducts were connected to two pressure sources (p1 and p2) of the oscillatory system by 454 
Teflon tubes (ID=0.8mm, OD=1.6mm;  Bola, Germany). The valves were initially closed, and 455 
the atmospheric pressure acted on the sample. 456 
In the first run, we applied p1=250 mmHg overpressure and p2= 0 mmHg (i.e. atmospheric 457 
pressure) and oscillation frequency of ~280/minute as described above.  458 
The inlet channel (from the side of the oscillatory system) was filled with the sample liquid 459 
only half-way. As the pressure was oscillating in the microfluidic device, rapid movement of 460 
the liquid meniscus could be observed according to the oscillation frequency (see Fig 3b-d). 461 
The overpressure p1 pushed the liquid meniscus towards the chamber, while upon switch to 462 
the low pressure (p2) the meniscus pulled back. Unfortunately, since the liquid was in direct 463 
contact with the oscillating air some evaporation occurred. As a consequence, the sample 464 
liquid evaporated from the chamber within approximately 40 min of starting the experiment, 465 
leaving the microfluidic chamber dry. 466 
 467 
PDMS sample chamber in the shape of a micro centrifuge-tube 468 
To avoid evaporation, we constructed a different microfluidic device, where the sample 469 
liquids were not in direct contact with the oscillating air. Briefly, we removed the caps of four 470 
0.5 mL conical bottom micro centrifuge tubes (Eppendorf, Germany) and glued them to a 471 
microscope glass slide (75x24x1 mm) in a line separated by ~3 mm from each other. On two 472 
other, larger glass plates (75x50x1 mm), we glued small blocks of polycarbonate (45x15x5 473 
mm) and fixed them on two opposing sides of the micro-centrifuge tube array, so that the 474 
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distance between the polycarbonate blocks and the tubes from both sides was ~1mm. We put 475 
this construction into a small box, filled it with polydimethylsiloxane (PDMS elastomer, 476 
Sylgard 184 mixed with curing agent at a ratio of 10:1 and degassed) and polymerized the 477 
PDMS at 75°C for 2 hours. After that, we removed it from the container, removed the glass 478 
plates, the polycarbonate blocks and micro centrifuge tubes from the cured PDMS. Next, we 479 
bonded the PDMS block from the two sides, where the removed polycarbonate blocks left a 480 
cuboid-shaped cavity to glass plates (75x50x1 mm) using oxygen plasma. We also inserted 481 
steel capillaries (OD = 0.8 mm) from two sides of each cavity to which we connected the 482 
oscillatory system by Teflon tubes (Bola, Germany). Next, we constructed a 4 mm thick 483 
PDMS plate to cover the top of the chamber array, which was left open after the Eppendorf 484 
tubes were removed from the PDMS. Prior to bonding with oxygen plasma, holes were 485 
punched in the PDMS cover to allow for sample injection. Once the microdevice was ready 486 
(see Figure 4d), we injected the sample liquids through the punched inlet holes into the 487 
sample chambers and sealed the inlet holes air-tight. The sample liquids filled the chamber 488 
completely. In a separate experiment we left small air bubbles in the Eppendorf-chambers for 489 
pressure estimation (see below). 490 
Operation parameters. After the chambers were filled the oscillatory system was turned on 491 
using pressures p1 = 2.5 bar and p2 = 500 mbar (equivalent to 1875 and 375 mmHg, 492 
respectively). Pressure higher than 2.5 bar resulted in destruction of the PDMS membrane 493 
between the sample chambers and the pressurized cavity. As the high-pressure air filled the 494 
cuboidal-cavities, they expanded and pushed the 1 mm thick PDMS membrane towards the 495 
sample-filled chambers squeezing and deforming them (the glass on the other side of the 496 
cavity  prevented the expansion) (see Figure 4b-c). As the valve of the high-pressure source 497 
(p1) closed and the second valve opened, the pressure in the cavity dropped significantly and 498 
the deformed sample chambers returned to their original shape. The rapid oscillation of the air 499 
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pressure (~280/min) in the cavities resulted in a corresponding squeeze-release pulsation of 500 
the chambers, mimicking a beating heart better than previous method.  After 24 hours of 501 
operation, the system was turned off, the plugs were removed from the inlet holes and the 502 
samples were removed with a syringe and needle for analysis. 503 
Pressure-bottle-pressure significantly exceeding the physiological range  504 
We put 4 samples into four 0.5 mL micro-centrifuge tubes (Eppendorf tubes), removed the 505 
caps of the tubes and covered them with parafilm (Bemis, USA) instead. Small holes were 506 
made in the parafilm with a syringe needle (OD = 0.6 mm). We put the sample-loaded 507 
Eppendorf tubes inside a 250 mL laboratory glass bottle (Duran™, Fischer Scientific, 508 
Germany) and closed it air-tight with a screw cap. Before closing, two small holes were 509 
drilled in the cap and steel capillaries (OD = 0.8 mm) were placed in and glued with an 510 
epoxy-based resin. The oscillatory system was connected to the steel capillaries with Teflon 511 
tubes. 512 
Operation parameters. In this experiment, we decided to work well above the target pressure 513 
range, in order to increase the chance of protein denaturation. After a few pilot experiments, 514 
we set the high pressure p1 equal to 4.5 bar (3375 mmHg) and the lower pressure p2 equal to 515 
0.5 bar (375 mmHg). However, due to the relatively large volume of the bottle, high 516 
compressibility of the air and the short opening times of the two valves, the pressures acting 517 
on the samples were not equal to the input pressures p1 and p2. 518 
To measure the actual pressure range inside the laboratory bottle, which acted directly on the 519 
samples, we attached two manometers (model 82100, AZ Instruments, Taiwan) to the 520 
pressure outlet of the setup: one before the second valve to measure the pressure that build-up 521 
inside the laboratory bottle and another behind the second valve to measure the pressure after 522 
the release (Figure 5). 523 
In the laboratory bottle the pressure acting on our samples never dropped below 450 mbar 524 
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(320 mmHg) and increased up to 1600 mbar (1200 mmHg). The frequency oscillation of the 525 
pressure was ~230/min with some “desynchronization” events every 15-20 s when the 526 
pressure difference Δp=p1-p2 was only ~150 mbar (110 mmHg). Whereas during 527 
synchronized operation, the pressure difference was ~ 600 mbar (450 mmHg).  528 
Proteins under hydrostatic pressure stress (HPS) 529 
In all experiments, proteins at a concentration of around 1 μmol/L were incubated in the 530 
pressure oscillation system for 24 hrs at room temperature. In each experimental run, we 531 
incubated in parallel proteins suspended in pure phosphate buffer saline (PBS) and 1M 532 
solution of TMAO in PBS. As a control for each of the samples, the solutions were divided 533 
into portions, where one portion was placed in a chamber exposed to oscillatory pressure 534 
while the other portion was placed in the same chamber but exposed to a constant, 535 
atmospheric pressure. All other conditions were the same for control and experimental 536 
samples. All solutions were then diluted 100-fold in PBS and fluorescence correlation 537 
spectroscopy (FCS) measurements were performed. 538 
Proteins under thermal stress 539 
LDH solutions (3, 30, 300 nM), in either pure PBS or PBS supplemented with 1M TMAO, 540 
were pipetted into Eppendorf tubes. Samples were placed in a water heat bath (Lauda, 541 
electronically controlled) and incubated for 15 minutes (in separate tests – data not shown 542 
here – we verified that prolonging the incubation time above this limit, up to 1 hour, did not 543 
influence the results). Next, samples were immersed in room-temperature water bath to cool 544 
down and FCS measurement was performed for samples equilibrated to 25°C. 545 
Fluorescence correlation spectroscopy 546 
The effect of hydrodynamic and thermal stress on Atto 488 (ATTO-TEC GmbH) labeled 547 
LDH structure was evaluated by means of FCS. Proteins were labeled using active NHS 548 
esters, according to a protocol supplied by the manufacturer. A 10-fold excess of the dye was 549 
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used to ensure a high degree of labeling (which was especially important for LDH, where we 550 
intended to have at least one label per subunit to be able to monitor probe concentration 551 
changes upon dissociation of the tetramer). Post-labeling purification was performed using 552 
Bio-Rad BioGel P-30 size exclusion columns. Protein labeling and purification was 553 
performed immediately before starting each experimental run. Protein diffusion coefficients 554 
(𝐷) are associated with the protein’s hydrodynamic radius (𝑅ℎ) by Stokes-Einstein relation, 555 
𝐷 = 𝑘𝐵𝑇/6𝜋𝜂𝑅ℎ (where 𝑘𝐵 is Boltzmann constant, 𝑇 is the temperature and 𝜂 denotes the 556 
viscosity of medium). The alteration in protein structure by dissociation of the quaternary 557 
structure results in an increase of the observed diffusion coefficient, while denaturation of 558 
tertiary structure  causes a decrease of 𝐷 by a factor of 1.5 – 3 (42).  559 
FCS measurements were performed on dedicated FCS system, based on a Nikon C1 inverted 560 
confocal microscope (Nikon Instruments, Japan) with a PlanApo 60x, NA=1.2 water 561 
immersion objective. The setup is equipped with a Pico Harp 300 system (PicoQuant, 562 
Germany). Measurements were performed in a climate chamber (Okolab, Italy) providing 563 
temperature control and required humidity at 25.0 ± 0.5℃. Labeled proteins were excited by 564 
a 485 nm laser, and fluorescence was detected through a 488/LP long-pass filter (Chroma, 565 
USA). Data acquisition and analysis was performed using SymPhoTime 64 software 566 
(PicoQuant, Germany). The experiments were preceded by establishing the dimension of the 567 
confocal volume using rhodamine 110 (Sigma-Aldrich, USA). 568 
Data analysis and statistics 569 
Blinding was provided for each treatment (TMAO vs control). Unblinding was performed 570 
after statistical analysis. Any encountered outliers were included in the analysis. Diastolic 571 
arterial blood pressure (DBP), systolic arterial blood pressure (SBP) and heart rate (HR) were 572 
calculated from the arterial blood pressure tracing. Left ventricular end-diastolic pressure 573 
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(LVEDP), maximal slope of systolic pressure increment (+dP/dt) and diastolic pressure 574 
decrement (-dP/dt) were calculated from the left ventricle blood pressure tracing using 575 
AcqKnowledge Biopac software (Biopac Systems, Goleta, USA). The Shapiro-Wilk test was 576 
used to test normality of the distribution. Differences between the TMAO and control groups 577 
were evaluated by an Independent-Samples t-test or by Mann-Whitney U test for data that 578 
were not normally distributed. In the acute experiments, the differences in the mean values 579 
between groups were first analyzed by the classic one-way ANOVA followed by a modified 580 
Student’s t-test for independent variables, using Bonferroni’s correction for multiple 581 
comparisons. The log-rank test was used to test the survival differences between TMAO and 582 
control animals. A value of two-sided p<0.05 was considered significant. Analyses were 583 
conducted using Statistica, version 13.3 (Tibco, Palo Alto, CA, USA). 584 
Replicates 585 
Replicates were not used unless otherwise stated. The basic definitions of technical and 586 
biological replicates are as follows. Technical replicates: a test performed on the same sample 587 
multiple times. Biological replicates: a test performed on biologically distinct samples 588 
representing an identical time point or treatment dose. 589 
Sample size 590 
Sample size was calculated at the start of the study, based on plasma levels of the investigated 591 
markers and hemodynamic parameters in rats, which were reported in our previous studies 592 
(11). We have chosen between-group difference in plasma NT-proBNP, ejection fraction, 593 
stroke volume and ABP as primary end-points with the following parameters, respectively: 594 
the difference between the tested (groups) 30%, 15%, 30% and 13%; the average for the 595 
entire population of 30 pg/mL, 80%, 0.35mL, 100mmHg; a common standard deviation of 7 596 
pg/mL, 9%, 0.08mL, 10mmHg; for an alpha error of 0.05, test power 0.8. Other biochemical 597 
parameters were used as secondary end points.  598 
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FIGURE LEGENDS 
Figure 1 Schematic illustration of experimental series. 6-week-old rats started drinking either 
water (control) or a TMAO solution. SHHF - Spontaneously Hypertensive Heart Failure 
(SHHF/MccGmiCrl-Lepr
cp
/Crl) SHHF, SD – Sprague-Dawley rats, SD-ISO - SD rats treated 
with ISO at the age of 56 week.  ISO - administration of isoprenaline at a dose of 100 mg/kg 
s.c. T1 - metabolic and echocardiographic measurements, T2 - echocardiographic 
measurements, T3 - metabolic, echocardiographic and direct hemodynamic measurements.  
Figure 2 Schematic illustration of the oscillatory pressure controller. 
Figure 3 a) Scheme of the experimental setup with the heart-shaped polydimethylsiloxane 
(PDMS) microfluidic device. b) time-sequence snapshots of the device in operations. From 
left to right: the device is filled with liquid and is at rest (for better visualisation we used here 
red-dyed water instead of the transparent protein solution). The microchannel connecting the 
pressure system to the microfluidic chamber is filled halfway. Applying high pressure (valve 
# 1 open) pushes the liquid meniscus towards the chamber. Closing valve # 1 and opening 
valve # 2 (low pressure) the liquid meniscus pulls back (even further than its original 
position). c) Close-up of the moving liquid meniscus, d) oscillation profile generated from the 
position of the liquid meniscus in the microchannel as a function of time for various pressure 
differences Δp=p1-p2. 
Figure 4 a) Scheme of the set-up with the pressure oscillator connected to the Eppendorf chip 
with side view and b) top view of the “Eppendorf chip”. Numbers indicate the glass slide (1), 
the sample chambers (2), the cuboidal cavity (3), the PDMS and the inlet (5) and outlet (6) 
steel capillaries, respectively. b-c) Schematic representation of the chip’s operation upon 
applied pressure: the cavity (3) expands towards the sample chambers (2) squeezing and 
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deforming them. d) Photo of the constructed device prior to filling and connecting to the 
pressure controller. 
Figure 5 Schematic representation of the “pressure bottle” system. Two manometers were 
attached to the system and used to determine the pressure acting on the samples. 
Figure 6 Echocardiography in 58-wk-old rats. SHHF - Spontaneously Hypertensive Heart 
Failure (SHHF/MccGmiCrl-Lepr
cp
/Crl), SD – Sprague-Dawley rats, SD-ISO: SD rats treated 
with ISO at the age of 56 week.  ISO: administration of isoprenaline at a dose of 100 mg/kg 
s.c. SD: Left ventricular systolic function is normal/preserved. Left and right ventricular 
diameter is normal. Left ventricular wall thickness is normal. Left atrial diameter is normal. 
SHHF: Septal hypokinesis. Left ventricular free wall is hypertrophic. Endocardium is 
hyperechogenic. SD-ISO: Septal hypokinesis. Left ventricular end-systolic diameter is 
increased. Left atrial enlargement. 
Figure 7 Histopathological picture of the heart, lungs and kidneys in the Sprague-Dawley rats 
drinking either water (control group) or TMAO solution. A - myocardium; haematoxylin-
eosin staining at magnification x10; B - myocardium; haematoxylin-eosin staining at 
magnification x40; C - myocardium; van Gieson staining at magnification x10; D - lungs; 
haematoxylin-eosin staining at magnification x10; E – kidney - renal cortex, renal bodies; 
haematoxylin-eosin staining at magnification x40; F - kidney - renal medulla; hematoxylin-
eosin staining at magnification x10. 
Figure 8 Real-time RT-PCR analysis, heart. Box plot comparing the expression profiles of 
ATG (angiotensinogen), AT1A (angiotensin II receptor type 1a), AT1B (angiotensin II 
receptor type 1b), AT2 (angiotensin II receptor type 2), TGF-b (transforming growth factor-
beta), TIMP2 (metalloproteinase inhibitor 2) in hearts of SD – Sprague-Dawley rats, SHHF - 
Spontaneously Hypertensive Heart Failure (SHHF/MccGmiCrl-Lepr
cp
/Crl), SD-ISO - SD rats 
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treated with ISO at the age of 56 week, drinking either water (control groups) or TMAO 
solution, (n=6-7 for each series). × - mean value, * indicates significant difference compared 
with the control group. *p < 0.05 by t-test or Mann-Whitney U test. 
Figure 9 Real-time RT-PCR analysis, kidneys. Box plot comparing the expression profiles of 
ATG (angiotensinogen), AT1A (angiotensin II receptor type 1a), AT1B (angiotensin II 
receptor type 1b), AT2 (angiotensin II receptor type 2), renin in kidneys of SD – Sprague-
Dawley rats, SHHF - Spontaneously Hypertensive Heart Failure (SHHF/MccGmiCrl-
Lepr
cp
/Crl), SD-ISO - SD rats treated with ISO at the age of 56 week, drinking either water 
(control groups) or TMAO solution, (n=6-7 for each series). × - mean value,* indicates 
significant difference compared with the control group. *p < 0.05 by t-test or Mann-Whitney 
U test. 
Figure 10 Histopathological picture of the heart, lungs and kidneys in Spontaneously 
Hypertensive Heart Failure (SHHF/MccGmiCrl-Lepr
cp
/Crl) drinking either water (control 
group) or TMAO solution. A - myocardium; hematoxylin-eosin staining at magnification x10; 
B - myocardium; hematoxylin-eosin staining at magnificarion x40; C - myocardium; van 
Gieson staining at magnification x10; D - lungs; hematoxylin-eosin staining at magnification 
x10; E – kidney - renal cortex, renal bodies; hematoxylin-eosin staining at magnification x40; 
F – kidney - renal medulla; hematoxylin-eosin staining at magnification x10; G – Percentage 
of myocardial fibrosis [%], N:C ratio of cardiomyocytes, values are means, ± SE. 
Figure 11 Survival Kaplan-Meier curves for SHHF - Spontaneously Hypertensive Heart 
Failure (SHHF/MccGmiCrl-Lepr
cp
/Crl) rats drinking either water (control group, n=9) or 
TMAO solution (n=9). Log-Rank test p = 0.06555 
Figure 12 Histopathological picture of the heart, lungs and kidneys in Sprague-Dawley rats 
treated with isoprenaline at the age of 56 weeks, and drinking either water (control group) or 
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TMAO solution. A - myocardium; haematoxylin-eosin staining at magnification x10; B - 
myocardium; haematoxylin-eosin staining at magnification x40; C - lungs; haematoxylin-
eosin staining at magnification x10; D – kidney - renal cortex, renal bodies; haematoxylin-
eosin staining at magnification x40; E – kidney - renal medulla; haematoxylin-eosin staining 
at magnification x10; F – Percentage of necrotic and inflammatory area in myocardium [%], 
values are means, ± SE. 
Figure 13 Effects of TMAO (n=8), urea (n=6) and saline (n=5) on renal excretion in 
anesthetized Sprague-Dawley rats. The priming dose (indicated by arrow) of TMAO and urea 
were 2.8 mmol/kg b.w. (bolus), followed by continuous infusion at a rate of 2.8 mmol/kg b.w. 
/ 60 min. V – urine flow; Uosm – urine osmolality; UosmV, UNaV, UKV – total solute, sodium 
and potassium excretion, respectively. Values are means ± SE.  * - p < 0.05 vs pretreatment 
values, 
#
 - p < 0.02 TMAO vs saline, TMAO vs urea. 
Figure 14 LDH incubated at a constant atmospheric pressure for 24 hrs or LDH exposed to 
oscillating pressure for 24 hrs with or without TMAO.  A - Diffusion coefficient of LDH 
incubated either in PBS buffer at a constant atmospheric pressure and room temperature  
(serving as a control) or exposed to pressure oscillation for 24 hrs either in PBS buffer or in 1 
M TMAO solution in PBS buffer at room temperature. Irrespective of the presence of 1M 
TMAO, 24-hour incubation under oscillating pressure did not cause dissociation, 
denaturation, or aggregation of LDH. B – Relative diffusion coefficient (diffusion coefficient 
𝐷 divided by its value in PBS buffer at room temperature 𝐷0) of LDH exposed to elevated 
temperatures for 15 min either in PBS buffer (black symbols) or 1 M TMAO solution in PBS 
(red symbols). Symbol shapes differentiate between three independent measurement series 
(series 1 (3nM of LDH) – squares, series 2 (30nM of LDH) – circles, series 3(300nM) – 
triangles). In series 1, we observed an increase in the relative diffusion coefficient, suggesting 
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degradation of LHD tetramer structure to monomers. In series 2 and 3, an increase in 
diffusion coefficient was followed by a decrease in diffusion coefficient suggesting the 
degradation of LDH followed by the aggregation of the LDH monomers. The presence of 
TMAO shifted the threshold of change in relative diffusion coefficient towards higher 
temperatures. 
SUPPLEMENTAL FIGURE LEGENDS 
Figure 7-figure supplement 1 Comparison of the histopathological picture between SD, 
SHHF and ISO-SD. 
A, B, C - myocardium; hematoxylin-eosin staining at magnification x10; D, E, F - 
myocardium; hematoxylin-eosin staining at magnification x40; G, H, I- myocardium; van 
Gieson staining at magnification x10; J, K, L - lungs; hematoxylin-eosin staining at 
magnificarion x10; M, N, O – kidney - renal cortex, renal bodies; hematoxylin-eosin staining 
at magnificarion x40; P, T, S – kidney - renal medulla; hematoxylin-eosin staining at 
magnification x10. 
Figure 14-figure supplement 1 Diffusion coefficients of LDH measured by FCS. First bar is 
a control; the two following correspond to samples incubated for 24 hours in the high-
pressure oscillation system without and with 1M TMAO in the solution. 
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TABLES 
Group/ 
Parameter 
SD-control SD-TMAO p 
Survival, energy and water balance 
Survival from the study onset (%, n)  100% (10/10) 100 % (10/10) - 
Body mass (g)  446.4±40.63 452.86±37.11 0.36 
24hr food intake (g)  19.99±2.83 21.49±2.64 0.12 
24hr water intake (g)  31.56±10.02 36.66±5.18 0.09 
24hr urine output (g)  18.66±2.35 22.66±6.49 0.04 
Tibia length (cm)  4.31±0.1 4.25±0.15 0.15 
TMAO 
Plasma TMAO (µmol/L)  6.55±0.65 39.73±20.6 <0.001 
24hr TMAO urine excretion (µmoles)  5.96±1.49 103.05±56.7 <0.001 
Heart mass 
Heart mass (g)  1.44±0.08 1.46±0.14 0.38 
Arterial blood pressure and heart rate 
Systolic (mmHg)  129.72±8.56 127.07±5.84 0.87 
Diastolic (mmHg)  80.56±13.3 86.61±9.74 0.15 
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HR (beats/min)  333.9±45 364.4±8.6 0.04 
Echocardiographic parameters 
LVEDV (mL)  0.47±0.15 0.57±0.1 0.06 
LVESV (mL)  0.12±0.04 0.13±0.03 0.44 
IVSs (cm)  0.35±0.03 0.35±0.03 0.42 
IVSd (cm)  0.24±0.03 0.25±0.03 0.19 
SV (mL)  0.36±0.11 0.44±0.1 0.04 
EF (%)  75.63±3.02 77.13±6.01 0.27 
Left ventricle hemodynamic parameters (direct measurements) 
LVEDP (mmHg)  4.12±0.78 4.25±0.92 0.45 
dP/dt (mmHg/ms)  6.54±1.02 7.31±1.23 0.12 
-dP/dt (mmHg/ms)  5.00±0.69 5.26±0.45 0.21 
Plasma NT-proBNP 
NT-proBNP (pg/mL)   24.79±8.1 18.61±8.17 0.22 
Electrolyte balance 
Serum sodium (mmol/L)  138.86±2.27 138.44±0.50 1.0 
24hr sodium urine excretion (mmoles)  1.76±0.23 2.11±0.08 0.003 
Serum potassium (mmol/L)  5.27±0.89 5.13±0.17 0.71 
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24hr potassium urine excretion (mmoles)  2.83±0.58 3.00±0.12 0.23 
Serum creatinine clearance (mL/min)  1.15±0.18 1.16±0.07 0.67 
Hormones 
Angiotensin II (pg/mL)  244.93±35.55 250.07±64.95 0.43 
Aldosterone (pg/mL)  897.05±95.34 925.61±75.29 0.27 
Vasopressin (ng/mL)   0.92±0.98 1.78±0.59 0.02 
Table 1. Metabolic, renal and cardiovascular parameters in 58-week-old normotensive 
Sprague-Dawley rats maintained on either water (SD-control, n=6-10) or TMAO solution 
(SD-TMAO, n=7-10).  
Creatinine clearance calculated as urine creatinine x urine output (ml/min) / plasma creatinine. 
LVEDV - left ventricle end diastolic volume, LVESV - left ventricle end systolic volume, SV 
– stroke volume, EF - ejection fraction, IVSs(d) - intraventricular septum diameter during 
systole and diastole, respectively, LVEDP - pressure in the left ventricle during the end of 
diastole measured directly with a catheter, +dP/dt - maximal slope of systolic ventricular 
pressure increment, - dP/dt - maximal slope of diastolic ventricular pressure decrement. 
Values are means, ± SD. P values by t-test or Mann-Whitney U test.  
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Group/ 
Parameter 
SHHF-control SHHF-TMAO p 
Survival, Energy and water balance 
Survival from the onset of the study (%, n)  66% (6/9) 100 % (9/9) 0.07 # 
Body mass (g)  475.2±17.1 476.3±12.1 0.43 
24hr food intake (g)  23.2±3.2 24.2±2.3 0.26 
24hr water intake (mL)  37.5±7.5 41.1±6.6 0.17 
24hr urine output (mL)  14.8±2.8 17.9±2.5 0.02 
Tibia length (cm)  3.95±0.21 3.99±0.11 0.34 
TMAO 
Plasma TMAO (µmol/L)  6.71±1.49 20.32±7.21 <0.001 
24hr TMAO urine excretion (µmoles)  9.97±3.46 126.8±32.8 <0.001 
Heart mass 
Heart mass (g)  1.87±0.31 1.72±0.3 0.19 
Arterial blood pressure and heart rate 
Systolic (mmHg)  136.2±12.8 126.8±12.7 0.11 
Diastolic (mmHg)  98.6±7.3 87.6±5.6 0.004 
HR (beats/min)  314±61 302±20 0.31 
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Echocardiographic parameters 
LVEDV (mL)  0.37±0.19 0.52±0.20 0.11 
LVESV (mL)  0.14±0.08 0.15±0.1 0.41 
IVSs (cm)  0.41±0.01 0.35±0.09 0.21 
IVSd (cm)  0.29±0.05 0.27±0.07 0.28 
SV (mL)  0.24±0.12 0.36±0.12 0.053 
EF (%)  64±8.5 71±6.1 0.06 
Left ventricle hemodynamic parameters (direct measurements) 
LVEDP (mmHg)  3.10±0.78 3.41±1.95 0.87 
dP/dt (mmHg/ms)  5.88±0.92 5.50±0.98 0.41 
-dP/dt (mmHg/ms)  2.35±0.28 2.55±0.67 0.27 
Plasma NT-proBNP 
NT-proBNP (pg/mL)   52.26±.15.0 42.80±9.5 0.09 
Electrolyte balance 
Serum sodium (mmol/L)  142.4±3.31 138.9±2.98 0.04 
24hr sodium urine excretion (mmoles)  1.42±0.28 1.93 ± 0.33 0.005 
Serum potassium (mmol/L)  4.73±0.33 4.49±0.28 0.09 
24hr potassium urine excretion (mmoles)  2.89±0.42 3.40±0.54 0.04 
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Serum creatinine clearance (mL/min)  0.42±0.17 0.53±0.05 0.06 
Hormones 
Angiotensin II (pg/mL)  325.7±39.8 276.7±38.3 0.02 
Aldosterone (pg/mL)   816.8±300.4 758.4±142.8 0.32 
Vasopressin (ng/mL)   3.02±1.24 3.11±1.03 0.45 
Cytokines 
TNF-a (pg/mL)  34.56±24.69 24.98±7.92 0.19 
IL-10 (pg/mL)  15.91±4.66 28.17±14.39 0.036 
 
Table 2. Metabolic, renal and cardiovascular parameters in 58-week-old Spontaneously 
Hypertensive Heart Failure (SHHF/MccGmiCrl-Lepr
cp
/Crl) rats maintained on either water 
(SHHF-control, n=5-6) or TMAO solution (SHHF-TMAO, n=7-9). 
Creatinine clearance calculated as urine creatinine x urine output (ml/min) / plasma creatinine. 
LVEDV - left ventricle end diastolic volume, LVESV - left ventricle end systolic volume, SV 
– stroke volume, EF - ejection fraction, IVSs(d), intraventricular septum diameter during 
systole and diastole, respectively. LVEDP - pressure in the left ventricle during the end of 
diastole measured directly with a catheter, +dP/dt - maximal slope of systolic ventricular 
pressure increment, - dP/dt - maximal slope of diastolic ventricular pressure decrement. 
Values are means, ± SD. p values by t-test or Mann-Whitney U test, except # - by log-rank 
test. 
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Group/ 
Parameter 
ISO-control ISO-TMAO 
 
p 
Survival, Energy and water balance 
Survival from the study onset 
(%, n) 
 90% (9/10) 100 % (10/10) 0.32# 
Body mass (g) T1 434.44±22.93 432.69±37.59 0.45 
T3 438.67±23.99 428.71±37.14 0.25 
24hr food intake (g) T1 21.54±1.43 21.84±1.94 0.51 
T3 21.24±2.44 22.08±1.91 0.21 
24hr water intake (mL) T1 34.99±3.10 34.82±3.89 0.53 
T3 34.77±5.47 35.59±1.92 0.34 
24hr urine output (g) T1 19.28±2.73 20.03±4.42 0.34 
T3 19.68±4.29 20.23±2.6 0.37 
Tibia length (cm) T3 4.33±0.06 4.34±0.1 0.35 
TMAO 
Plasma TMAO (µmol/L) T3 5.95±2.35 32.51±11.43 <0.001 
24hr TMAO urine excretion 
(µmoles) 
T3 5.74±1.64 119.12±65.96 <0.001 
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Heart mass 
Heart mass (g) T3 1.46±0.13 1.43±0.19 0.39 
Arterial blood pressure and heart rate 
Systolic (mmHg) T3 142.48±10.63 130.92±11.67 0.026 
Diastolic (mmHg) T3 97.10±9.95 87.59±10.47 0.037 
HR (beats/min) T3 356.56±23.39 344.19±49.69 0.26 
Echocardiographic parameters 
LVEDV (mL) T1 0.44±0.22 0.33±0.17 0.15 
T2 0.54±0.22 0.53±0.23 0.47 
T3 0.51±0.11 0.53±0.34 0.21 
LVESV (mL) T1 0.13±0.09 0.11±0.07 0.31 
T2 0.22±0.13 0.13±0.05 0.054 
T3 0.12±0.05 0.08±0.02 0.01 
IVSs (cm) T1 0.33±0.03 0.32±0.05 0.29 
T2 0.33±0.06 0.35±0.09 0.29 
T3 0.36±0.04 0.32±0.05 0.07 
IVSd (cm) T1 0.24±0.04 0.23±0.04 0.28 
T2 0.26±0.03 0.25±0.04 0.41 
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T3 0.24±0.04 0.25±0.03 0.31 
SV (mL) T1 0.29±0.15 0.26±0.12 0.40 
T2 0.35±0.17 0.47±0.22 0.09 
T3 0.38±0.09 0.34±0.07 0.69 
EF (%) T1 71.22±6.12 72.11±14.51 0.45 
T2 73.11±8.88 70.11±12.84 0.28 
T3 78.67±7.18 77.89±11.94  0.43 
Left ventricle hemodynamic parameters (direct measurements) 
LVEDP (mmHg) T3 6.73±2.55 4.46±0.74 0.03 
dP/dt (mmHg/ms) T3 9.20±1.54 6.55±1.18 0.004 
-dP/dt (mmHg/ms) T3 5.19±0.38 4.76±0.65 0.09 
Plasma NT-proBNP 
NT-proBNP (pg/mL) T3 64.49±43.59 22.01±22.83 0.02 
Electrolyte balance 
Serum sodium (mmol/L) T3  136.88±3.56 137.89±1.62 0.23 
24hr sodium urine 
excretion (mmoles) 
T3 1.93±0.27 2.09±0.42 0.18 
Serum potassium (mmol/L) T3 5.53±0.89 5.02±0.77 0.11 
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24hr potassium urine 
excretion (mmoles) 
T3 2.56±0.35 2.92±0.35 0.03 
Serum creatinine clearance 
(mL/min) 
T3 1.26±0.23 1.24±0.26 0.43 
Hormones 
Angiotensin II (pg/mL) T3 286.4±24.4 272.6±39.5  0.35 
Aldosterone (pg/mL)  T3 938.6±114.6 1032.4±120.6 0.07 
Vasopressin (ng/mL)  T3 0.98±0.55 1.28±0.66 0.18 
Table 3. Metabolic, renal and cardiovascular parameters in 58-week-old normotensive 
Sprague-Dawley rats treated with isoprenaline at the age of 56 weeks. Rats maintained on 
either water (ISO-control, n=5-9) or TMAO solution (ISO-TMAO, n=7-10). T1 - metabolic 
and echocardiographic measurements, T2 - echocardiographic measurements, T3 - metabolic, 
echocardiographic and direct hemodynamic measurements (see also the study design, Figure 
1). Creatinine clearance calculated as urine creatinine x urine output (ml/min) / plasma 
creatinine. LVEDV - left ventricle end diastolic volume, LVESV - left ventricle end systolic 
volume, SV – stroke volume, EF - ejection fraction, IVSs(d), intraventricular septum diameter 
during systole and diastole, respectively. LVEDP - pressure in the left ventricle during the end 
of diastole measured directly with a catheter, +dP/dt - maximal slope of systolic ventricular 
pressure increment, - dP/dt - maximal slope of diastolic ventricular pressure decrement. 
Values are means, ± SD. P values by t-test or Mann-Whitney U test, except # - by log-rank 
test. 
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